Abstract
The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1288-1291 |
| Number of pages | 4 |
| Journal | Lupus |
| Volume | 23 |
| Issue number | 12 |
| DOIs | |
| State | Published - Oct 8 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Rheumatology
Fingerprint
Dive into the research topics of 'Cardiovascular disease in the antiphospholipid syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver